Newsroom
Sorted by: Latest
-
PharmaEssentia Announces FDA Approval and U.S. Launch of BESREMi Pen™ (ropeginterferon alfa-2b-njft) for Polycythemia Vera
BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced the U.S. Food and Drug Administration (FDA) approval and launch of the BESREMi Pen™ (ropeginterferon alfa-2b-njft) device for adult patients with polycythemia vera (PV). The device offers a mor...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 25.06.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,402,277.56 28.044 ...
-
Sila Realty Trust, Inc. Stockholders Approve Acquisition by Affiliates of Blue Owl Capital Inc.
TAMPA, Fla.--(BUSINESS WIRE)--Sila Realty Trust, Inc. Stockholders Approve Acquisition by Affiliates of Blue Owl Capital Inc....
-
Sinda to Begin Trading on NYSE
NEW YORK--(BUSINESS WIRE)--Sinda Ltd. (the “Company” or “Sinda”), a silver exploration company with mineral projects in Mexico, will begin trading today on the New York Stock Exchange (the “NYSE”) under the ticker symbol “SIND”. Daniel Muñiz Quintanilla, Executive Chairman, said: “Silver mining has been an important component of Mexico's economy for centuries. Today silver is an essential metal for the global energy transition and remains an important monetary metal. Sinda’s silver/gold deposit...
-
Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3
LONDON--(BUSINESS WIRE)-- Ap27 FORM 8.3 IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE 1. KEY INFORMATION (a) Full name of discloser Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a) The naming of nominee or vehicle companies is insufficient. For...
-
Aquila Air Capital Upsizes Credit Facility to $400 Million
DUBLIN--(BUSINESS WIRE)--Aquila Air Capital (“Aquila”), a leading lessor based in Ireland and backed by funds managed by global alternative asset manager Wafra Inc., announced today the closing of a $400 million refinancing and upsizing of its Warehouse Facility with ATLAS SP Partners (“ATLAS”), the warehouse finance and securitized products business majority owned by Apollo funds. With this expanded facility, Aquila is well positioned to grow its already robust and diversified engine portfolio...
-
First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)
LONDON--(BUSINESS WIRE)-- Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust US Large Cap Core AlphaDEX UCITS ETF 25.06.2026 FEXD.LN IE00BWTNMB87 453,848.00 USD 46,582,563.38 102.639 ...
-
Semrush Releases Expanded 2026 AI Visibility Index, Analyzing 126 Million AI Search Prompts
BOSTON--(BUSINESS WIRE)--Semrush Releases Expanded 2026 AI Visibility Index, Analyzing 126 Million AI Search Prompts...
-
Léa Dunand-Chatellet Appointed Chief Executive Officer of Mirova
PARIS--(BUSINESS WIRE)--Natixis Investment Managers (Natixis IM) today announces the appointment of Léa Dunand-Chatellet as Chief Executive Officer of Mirova, its affiliate dedicated to sustainable investing. Léa Dunand-Chatellet’s appointment was approved today by Mirova’s Board of Directors. She will assume her role on July 1, 2026, succeeding Philippe Zaouati. With over twenty years of experience in sustainable investing, Léa Dunand-Chatellet has worked for leading asset management firms, in...
-
Shionogi to Partner with ALS/MND Natural History Consortium to Collect Real-World Data in ALS, Reinforcing Investments in ALS Research
FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter, “Shionogi”) today announced its continued partnership with the ALS/MND Natural History Consortium (Consortium) to collect real-world data in amyotrophic lateral sclerosis (ALS). The goal of this collaboration is to deepen scientific knowledge of ALS through access to real-world data, including data of approved therapies for ALS, such as RADICAVA OR...